To get to the bottom of this perplexing behavior, Science interviewed the agent

The NIH continued reducing grants involving health disparities, race, and ethnicity but made little progress toward other administration priorities in the 2026 fiscal year.

A small conference with big ambitions mirrors the rapid growth of Chinese biotech, invites comparisons to U.S. biotech gathering also known for deal-making.

Scientists have found a human gene lurking in a virus that causes skin infections. It may be using our own DNA to infect us.

Senators focused on asking Overton about vaccines, abortion, and vapes.

Several members of Congress voiced strong opposition about a reported plan to create a panel of political appointees to sign off on NIH grants

The FDA's plan to hire thousands of new workers is being slowed by an overwhelmed HR center.

Health secretary RFK Jr. returned to his roots in a keynote address at a conference hosted by the Children’s Health Defense, an anti-vaccine nonprofit he helped start.

International researchers got a reprieve in the courts this week. What does that mean for U.S. medical research? Find out on this week's episode of "The Readout LOUD" podcast.

A federal judge halted a Trump administration plan to place a four-year cap on the kinds of visas used by graduate students and postdocs

Hospital leaders were excited about the Rural Health Transformation Fund until they saw the fine print.

Platinum chemotherapy aged the liver cells of treated children, making them look more like adult liver cells and possibly raising the long-term risk of new tumors

Caspian Therapeutics, is launching with $50 million in financing to develop menin inhibitors for diabetes and other cardiometabolic diseases.

CEOs of the biggest AI companies have predicted the technology will “eliminate most cancer” and “improve treatment of most other ailments.” But nowhere better illustrates the challenge facing AI than ...

An NIH proposal to cap the number of research grants investigators can receive has drawn a mixed reception, the agency says.

Agency gives university-industry consortium $47 million to reinvent existing internship program

Marc Tessier-Lavigne released new details from his research and travel in an attempt to refute allegations in a new book that he published fraudulent results.

Some comments on a proposed OMB research rule have been mysteriously removed from a public-facing government webpage.

Urologic oncologists who treat prostate cancer are split over the benefits of focal therapy compared to traditional surgery or radiation.

If she wins confirmation as FDA commissioner, Heidi Overton will face plenty of big challenges.

A personalized mRNA cancer vaccine succeeded in a late-stage melanoma study, results that could herald a new, powerful approach in oncology.

Colorado biotech Enveda reports preliminary results on a drug to help people maintain weight loss after GLP-1 use. Just don't call it exercise in a pill.

DHS was sued Tuesday over a sweeping policy change that would limit how long foreign students and scholars can remain in the U.S.

The NIH plans to close the door on one of the few pathways available to international students on visas to forge a career in biomedical research in the U.S.

A Senate committee has voted to hold Anthony Fauci in contempt of Congress after he declined to answer questions about his role in the Covid pandemic.

The protein tau is top target for Alzheimer’s drug development, and a new study bolsters those efforts by describing a previously unknown role that tau plays in neurodegeneration.

With a second delayed report of a child's death in China, criticism is rising of a looser form of clinical trial. One expert: what "bothers me is the lack of transparency."

Doctors are asking how to get retatrutide for their patients, after Eli Lilly gave one man early access.

Young life scientists have been increasingly abandoning academia, a seismic shift that has fueled calls for rethinking graduate education. On Wednesday,

Latigo Biotherapeutics published positive data for an acute-pain drug meant to rival a Vertex medicine already on the market

A Trump administration plan to limit visas for graduate student and postdocs to four years is fueling concerns that the U.S. could lose out on foreign scientists

The Trump administration released its blueprint for U.S. science, calling for shifting hundreds of billions of research dollars from universities to industry.

Schwartz's background as a physician with plenty of government service experience will likely be popular among lawmakers.

The Trump administration is weighing how to respond to a court ruling on vaccine policymaking, a decision that could come with political risks.

A nationwide STAT survey of NIH-funded researchers reveals that, a year after Donald Trump's return to the White House, many scientists are reeling

Adam Sherwat, the director of the Office of Infectious Diseases in the FDA’s Center for Drug Evaluation and Research, is leaving the agency.

NIH Director Jay Bhattacharya promised a House subcommittee on Tuesday that the agency will spend its full budget by the end of the 2026 fiscal year

Breaking: A federal judge on Monday stalled major parts of health secretary Robert F. Kennedy Jr.’s campaign to remake vaccine policy in the U.S.

Vinay Prasad's unique ability to attract criticism — even when his bosses, including the president, wanted him to keep his head low — did him in at the FDA.

Prasad has been involved in several controversial decisions related to rare disease treatments.

Trump wants to focus on his efforts to lower drug prices, but the TrumpRx website is falling short of his promises.